Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 29, 2026 | $0.61 | +15.1% | $5.44B | +7.5% | $0.83 |
| Q1 FY26ended Mar 31, 2026 | Apr 22, 2026 | $0.90 | +100.0% | $5.20B | +11.6% | $0.80 |
| Q4 FY25ended Dec 31, 2025 | — | $0.45 | +18.4% | $5.29B | +15.9% | — |
| Q3 FY25ended Sep 30, 2025 | — | $0.51 | +59.4% | $5.07B | +20.3% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.53 | +140.9% | $5.06B | +22.8% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.45 | +36.4% | $4.66B | +20.9% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.38 | +11.8% | $4.56B | +22.4% | — |
| Q3 FY24ended Sep 30, 2024 | — | $0.32 | −5.9% | $4.21B | +19.3% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Boston Scientific shares, not any token. As of Jul 29, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.22 | — | $4.12B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.33 | — | $3.86B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.34 | — | $3.73B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.34 | — | $3.53B | — | — |